DR5 Antibody (MD5-1) is a hamster monoclonal IgG antibody that detects DR5 in mouse samples through flow cytometry (FCM). DR5, also known as death receptor 5, is a crucial member of the tumor necrosis factor receptor superfamily and plays a significant role in mediating apoptosis, particularly in response to the cytokine TRAIL (TNF-related apoptosis-inducing ligand). Anti-DR5 antibody (MD5-1) recognizes a protein vital for regulating cell death and maintaining tissue homeostasis. When TRAIL binds to DR5, a cascade of intracellular signaling events leads to the recruitment of adaptor proteins and formation of the death-inducing signaling complex (DISC), ultimately resulting in apoptosis. This mechanism is particularly important in cancer biology, as many tumors exploit these pathways to evade programmed cell death, making DR5 a potential target for therapeutic interventions aimed at restoring apoptosis in cancer cells. DR5 (MD5-1) antibody serves as an essential tool for researchers studying these pathways and developing novel cancer treatments.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
DR5 Antibody (MD5-1) References:
- Apoptosis. DR5 unfolds ER stress. | Zlotorynski, E. 2014. Nat Rev Mol Cell Biol. 15: 498-9. PMID: 25027654
- Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer. | Mert, U. and Sanlioglu, AD. 2017. Cell Mol Life Sci. 74: 245-255. PMID: 27510421
- Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. | Dubuisson, A. and Micheau, O. 2017. Antibodies (Basel). 6: PMID: 31548531
- Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. | van der Horst, HJ., et al. 2021. Blood Adv. 5: 2165-2172. PMID: 33885752
- Induction of DR5-Dependent Apoptosis by PGA2 through ATF4-CHOP Pathway. | Park, KM., et al. 2022. Molecules. 27: PMID: 35744931
- Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5. | Woo, SM., et al. 2022. Cell Death Dis. 13: 821. PMID: 36153316
- cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. | Wang, L., et al. 2022. Nat Cancer. 3: 1284-1299. PMID: 36414711
- A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury. | Yang, C., et al. 2023. Nat Commun. 14: 4261. PMID: 37460623
- Glycyrrhetinic acid attenuates endoplasmic reticulum stress-induced hepatocyte apoptosis via CHOP/DR5/Caspase 8 pathway in cholestasis. | Zou, B., et al. 2023. Eur J Pharmacol. 961: 176193. PMID: 37981257
- ASB3 promotes hepatocellular carcinoma progression by mediating DR5 ubiquitination in TRAIL resistance. | Huang, L., et al. 2024. FASEB J. 38: e23475. PMID: 38334450